Brain Amylin Signaling, Feeding, and Reward - PubMed
4 days ago
- #amylin
- #pharmacotherapy
- #obesity
- Obesity is a costly and prevalent disease requiring new treatment approaches.
- Amylin, a pancreatic hormone, shows promise for obesity pharmacotherapies by suppressing feeding and body weight through brain actions.
- Initially, research focused on amylin's hindbrain sites, but recent studies highlight its influence on food intake and reward in mesolimbic structures.
- Amylin signaling affects both palatable food intake and other reinforcing stimuli like drugs of abuse.
- Amylin-based pharmacotherapies' broad effects should be considered in developing new obesity medications.
- Studies suggest synergistic effects of combining GLP-1 and amylin receptor agonists in reducing alcohol intake in rats.